Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Flynn, Neil M; Forthal, Donald N; Harro, Clayton D; Judson, Franklyn N; Mayer, Kenneth H; Para, Michael F

Flynn, Neil M; Forthal, Donald N; Harro, Clayton D; Judson, Franklyn N; Mayer, Kenneth H; Para, Michael F.

Affiliation

Flynn NM; University of California at Davis Medical Center, USA.

J Infect Dis ; 191(5): 654-65, 2005 Mar 01.

Article in En | MEDLINE | ID: mdl-15688278

Subject(s)

AIDS Vaccines; HIV Envelope Protein gp120/immunology; HIV Infections/prevention & control; HIV-1/immunology; AIDS Vaccines/immunology; Adolescent; Adult; Disease Progression; Female; Humans; Male; Middle Aged; Risk Factors; Risk-Taking; Time Factors; Vaccines, Synthetic/immunology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: HIV Envelope Protein gp120 / HIV Infections / HIV-1 / AIDS Vaccines Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: J Infect Dis Year: 2005 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links